Abstract / Summary
Obesity is a modifiable risk factor for asthma worldwide and is associated with poor asthma control. Weight loss is an effective intervention for patients with obesity and asthma; however, a consistent association between metabolic bariatric surgery (MBS) and asthma in patients with obesity is lacking. To assess the effects of MBS in patients with obesity and asthma, we conducted a meta-analysis of data from inception to February 2026. Thirty-three observational studies including 3731 patients were analyzed. A total of 47% of patients achieved discontinuation of asthma medication (95% CI, 0.38-0.56; p < 0.05), and 58% of patients achieved clinical asthma remission (95% CI, 0.45-0.70; p < 0.05). Additionally, MBS was associated with an 8.5% increase in forced expiratory volume in one second (FEV1) (95% CI, 4.5-12.6; p < 0.05) and a 9.4% increase in forced vital capacity (FVC) (95% CI, 6.3-12.6; p < 0.05). This evidence suggests that MBS results in clinical remission of asthma and improvement in pulmonary function in patients with obesity and asthma. KEY POINTS: •MBS can alleviate clinical asthma in patients with obesity. •MBS can improve FEV1 in patients with obesity and asthma. •MBS can improve FVC in patients with obesity and asthma.
Primary Source
Obesity surgery
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.